Last reviewed · How we verify
FLAVODIC ACID
FLAVODIC ACID is a flavodic acid drug. It is currently in Phase 2 development.
Flavodic acid is thought to work by interacting with a specific biological target to produce a therapeutic effect.
Flavodic acid is a small molecule drug in the flavodic acid class, but details about its development, ownership, and commercial status are not available. Its mechanism of action and target are also unknown. As a result, there is limited information available about its use, safety, and efficacy. Further research is needed to understand the potential benefits and risks of flavodic acid. Its current status and indications are unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FLAVODIC ACID |
|---|---|
| Drug class | flavodic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine flavodic acid as a key that fits into a lock on a cell. When it binds to the lock, it triggers a series of events that help to treat a particular condition. This process is complex and involves many different molecules and pathways, but essentially, flavodic acid helps to restore balance to the cell and alleviate symptoms.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FLAVODIC ACID CI brief — competitive landscape report
- FLAVODIC ACID updates RSS · CI watch RSS
Frequently asked questions about FLAVODIC ACID
What is FLAVODIC ACID?
How does FLAVODIC ACID work?
What drug class is FLAVODIC ACID in?
What development phase is FLAVODIC ACID in?
Related
- Drug class: All flavodic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing